Hosted on MSN5d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Zacks.com on MSN13d
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...
MRK Earnings: Weak 2025 Guidance Mangles Merck Stock Today
Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company ...
Yahoo Finance8d
Why Merck (MRK) Stock Is Falling Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...
AOL7d
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
Forbes26d
What’s In Store For Merck Stock In 2025?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...
Wall Street Journal8d
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
Merck MRK0.14%increase; green up pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...
Yahoo Finance27d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...
ABC News9d
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
Nasdaq13d
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...
Benzinga.com7d
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...